Foamix Offers New Intravaginal Foam Technology with Improved Usability &
NESS ZIONA, Israel, May 13 /PRNewswire/ -- Despite the high incidence of women's health conditions that require intra-vaginal drug delivery and the abundance of intravaginal creams, gels and ovules, a recent survey found that an alarming majority of women find their current treatment options "unacceptable" or "intolerable". The survey, conducted by Elixir-Applied Researches for Foamix, polled more than 200 women.
Findings show that the majority of females who have used intravaginal drugs find them dissatisfying because these products leak out of the vagina following treatment (72%), because of irritation, itch or bad smell (60%), or simply because they are inconvenient to use (58%). 82% of the panellists opined that they would trade their current medication for a new form that does not leak; and 65% would prefer a product that does not cause irritation, itch or bad smell.
Foamix develops foam delivery systems for intravaginal administration that expand gently in the vaginal cavity and evenly cover the entire vaginal surface for efficient treatment. The Foamix foams are administered in small and accurate amounts, (using metered dose valves). They are bioadhesive to reduce dosing frequency and are constituted of non-irritating ingredients. Notably, the Foamix foams are fully retained inside the vagina, resulting in non leakage and enhanced efficacy.
"It seems the majority of women are dissatisfied with the current intravaginal treatment options. Treatment inconvenience is known to result in poor treatment compliance and there is therefore still a need for new drug delivery systems that can be easily administered, enable adherence of drugs to the vaginal surface and do not leak out or cause irritation," says Arie Yeshaya, M.D., Senior Gynecologist at Rabin Medical Center, Israel (affiliated with Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel); and a women's health consultant to Foamix.
"The Foamix foam concept hits right on the spot of the drawbacks of current treatments," he adds.
"The Foamix intravaginal foam platform was developed with these difficulties in mind. We are working with major pharma companies to co-develop and market new intravaginal and dermal foam formulations," says Dr. Dov Tamarkin, CEO of Foamix Ltd.
Headquartered in Ness Ziona, Israel, Foamix Ltd. is a leading developer of topical foams for dermatology and gynecology. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. Foamix is currently collaborating with 10 pharmaceutical companies on 11 projects in the development of proprietary dermal and intravaginal drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation. Foamix holds 4 US patents and has 64 US patents pending, with further filings worldwide.
For additional information please visit http://www.foamix.co.il
Sigal Maymon, Foamix Ltd, +972-8-9316233 or firstname.lastname@example.org
|SOURCE Foamix Ltd|
Copyright©2008 PR Newswire.
All rights reserved